TScan Therapeutics Inc. (NASDAQ: TCRX)
$7.10
+0.3600 ( +5.34% ) 235.4K
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Market Data
Open
$7.10
Previous close
$6.74
Volume
235.4K
Market cap
$375.33M
Day range
$6.76 - $7.18
52 week range
$1.93 - $9.69
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 14, 2024 |
8-k | 8K-related | 16 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
3 | Insider transactions | 2 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
8-k | 8K-related | 13 | May 13, 2024 |
10-q | Quarterly Reports | 51 | May 13, 2024 |